Clinical Roundup Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds September 25, 2026Vol.52 No.35
Clinical Roundup PDS0101 + pembrolizumab in HPV16+ R/M head and neck cancer show anti-tumor activity, VERSATILE-002 phase II study finds September 25, 2026Vol.52 No.35
Clinical Roundup Blood test could guide future treatment in Ewing sarcoma, Dana-Farber study finds September 25, 2026Vol.52 No.35
Clinical Roundup COA survey finds high bispecific therapy adoption among community oncology practices September 25, 2026Vol.52 No.35
Clinical Roundup ASCO expresses support for functional precision medicine, rescinding past objections September 18, 2026Vol.52 No.34
Clinical Roundup EGFR mutation linked to dramatically increased lung cancer risk September 18, 2026Vol.52 No.34
Clinical Roundup Cancer biosimilars associated with lower costs for insurers and patients, UCLA study finds September 18, 2026Vol.52 No.34
Clinical Roundup AI may help identify breast cancers missed by mammograms, but clinical benefit remains uncertain, UCLA-led review finds September 18, 2026Vol.52 No.34
Clinical Roundup UT Southwestern scientists discover metabolite fueling aggressive brain tumor growth September 18, 2026Vol.52 No.34
Clinical Roundup OST-HER2-treated patients show statistically significant benefit in interim three-year OS analysis of phase IIb pulmonary metastatic osteosarcoma trial September 18, 2026Vol.52 No.34
